Demographic, clinical, and therapeutic characteristics of patients with juvenile idiopathic arthritis treated with etanercept. Data are numbers (percentages) unless otherwise indicated.
| Characteristic | All Patients, n = 173 | Patients with Inactive Disease, n = 87 | Patients with Active Disease, n = 86 | p* |
|---|---|---|---|---|
| Demographic data | ||||
| Female | 123 (71.1) | 62 (71.3) | 61 (70.9) | 0.961 |
| Age at disease onset, median (IQR), yrs | 3.6 (1.9; 7) | 3.1 (1.9; 5.9) | 4.1 (1.9; 8.1) | 0.107 |
| Interval between disease onset and first observation, median (IQR), yrs | 0.6 (0.2; 2.5) | 0.6 (0.2; 2.8) | 0.6 (0.2; 2.3) | 0.621 |
| Disease duration before start of etanercept, median (IQR), yrs | 5 (1.8; 8.2) | 5.2 (2.1; 8.8) | 4.1 (1.7; 7.7) | 0.210 |
| Interval between first observation and start of etanercept, median (IQR), yrs | 3 (0.7; 5.6) | 3.3 (0.8; 5.9) | 2.5 (0.7; 5.3) | 0.520 |
| Age at start of etanercept therapy, median (IQR), yrs | 9.9 (6.7; 14.3) | 9.8 (6.6; 14.3) | 10 (7.1; 14.1) | 0.904 |
| Duration of etanercept therapy, median (IQR), yrs | 2.2 (1.1; 3.5) | 2.2 (1.3; 3.2) | 2 (0.8; 3.6) | 0.379 |
| No. visits during etanercept therapy, median (IQR) | 5 (3; 9) | 5 (4; 8) | 5.5 (3; 10) | 0.854 |
| ILAR category | 0.022 | |||
| Systemic arthritis | 27 (15.6) | 8 (9.2) | 19 (22.1) | |
| Persistent oligoarthritis | 12 (6.9) | 7 (8) | 5 (5.8) | |
| Extended oligoarthritis | 70 (40.5) | 40 (46) | 30 (34.9) | |
| Rheumatoid factor-negative polyarthritis | 38 (22) | 18 (20.7) | 20 (23.3) | |
| Rheumatoid factor-positive polyarthritis | 7 (4) | 3 (3.4) | 4 (4.7) | |
| Psoriatic arthritis | 6 (3.5) | 1 (1.1) | 5 (5.8) | |
| Enthesitis-related arthritis | 12 (6.9) | 10 (11.5) | 2 (2.3) | |
| Undifferentiated arthritis | 1 (0.6) | 0 (0) | 1 (1.2) | |
| Patients with positive antinuclear antibodies (n = 169) | 105 (62.1) | 57 (67.1) | 48 (57.1) | 0.184 |
| JIA outcome measures at start of etanercept, median (IQR) | ||||
| Physician global assessment VAS score, cma (n = 153) | 6 (4; 8) | 5.5 (3.5; 7.8) | 6.0 (4.0; 8) | 0.254 |
| Parent global assessment VAS score, cma (n = 65) | 5 (3; 7) | 5 (2.5; 7.25) | 5.3 (4; 7) | 0.665 |
| Parent pain assessment VAS score, cma (n = 65) | 5 (3.1; 7.2) | 5 (3; 7.5) | 5 (3.5; 7.1) | 0.984 |
| Physical function scoreb (n = 65) | 0.6 (0.2; 0.9) | 0.4 (0.1; 0.8) | 0.7 (0.2; 0.9) | 0.103 |
| No. swollen joints (n = 153) | 4 (2: 9) | 3.5 (2; 7) | 4.5 (2; 10) | 0.169 |
| No. tender joints (n = 153) | 5 (2; 10) | 4.5 (2; 9) | 6 (3; 12) | 0.353 |
| No. restricted joints (n = 153) | 4 (2; 8) | 3 (2; 7) | 4 (3; 9) | 0.158 |
| No. active joints (n = 153) | 5 (2.5; 10) | 4 (2; 10) | 7 (3; 11) | 0.223 |
| Erythrocyte sedimentation rate, mm/hc (n = 151) | 40 (21; 59) | 39.5 (19; 61.5) | 40 (23; 52) | 0.978 |
| C-reactive protein, mg/dld (n = 148) | 1.4 (0.5; 4.7) | 1.2 (0.5; 4.4) | 1.8 (0.5; 5.2) | 0.391 |
| Joints affected before start of etanercept | ||||
| Cervical spine | 28 (16.2) | 10 (11.5) | 18 (20.9) | 0.092 |
| Wrist | 81 (46.8) | 30 (34.5) | 51 (59.3) | 0.001 |
| Hand joints | 95 (54.9) | 43 (49.4) | 52 (60.5) | 0.144 |
| Hip | 41 (23.7) | 18 (20.7) | 23 (26.7) | 0.349 |
| Knee | 136 (78.6) | 63 (72.4) | 73 (83.4) | 0.045 |
| Ankle | 131 (75.7) | 69 (79.3) | 62 (72.1) | 0.268 |
| Use of medications before start of etanercept | ||||
| Systemic corticosteroids | 70 (40.5) | 28 (32.2) | 42 (48.8) | 0.026 |
| Methotrexate | 165 (95.4) | 82 (94.3) | 83 (96.5) | 0.480 |
| Cyclosporine | 41 (23.7) | 16 (18.4) | 25 (29.1) | 0.099 |
| Sulfasalazine | 14 (8.1) | 5 (5.7) | 9 (10.5) | 0.255 |
| Intraarticular corticosteroids | 125 (72.3) | 61 (70.1) | 64 (74.4) | 0.527 |
| Concomitant medications during etanercept administration | ||||
| Systemic corticosteroids | 24 (13.9) | 8 (9.2) | 16 (18.6) | 0.073 |
| Methotrexate | 116 (67.1) | 53 (60.9) | 63 (73.3) | 0.084 |
| Intraarticular corticosteroids | 38 (22.0) | 10 (11.5) | 28 (32.6) | 0.0008 |
↵a 0–10 scale (0 = best; 10 = worst);
↵b 0–3 scale (0 = best; 3 = worst);
↵c normal < 20 mm/h;
↵d normal < 0.3 mg/dl.
↵* Comparisons of quantitative data by Mann-Whitney U test; comparisons of frequencies by chi-square test or Fisher’s exact test if expected frequencies were < 5. IQR: interquartile range; ILAR: International League of Associations for Rheumatology; JIA: juvenile idiopathic arthritis; VAS: visual analog scale.